Arrhythmias in Autoimmune Rheumatic Disease

Save

A new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis have an increased risk of arrhythmias and sudden cardiac death attributable to shared immune pathways.

$2 Million in Research Grants for Juvenile Arthritis

Save

July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.

Chikungunya Club Meeting (7.24.2026)

Save

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.

Interferon-α as an Immunologic Driver of Sjögren's Disease

Save

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

Save

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

ICYMI: VEXAS Syndrome - A Review

Save

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

ICYMI: EGPA Review

Save

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

EULAR26: Reports on Systemic Sclerosis

Save

In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).

2-Gene Blood Test for Kawasaki Disease in Febrile Children

Save

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. 

Do You Zoster Vaccinate? (6.19.2026)

Save

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Late-Breaking Studies at EULAR 2026

Save

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

EULAR 2026 Rheumatology RoundUp

Save

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

What’s New in Macrophage Activation Syndrome Therapeutics

Save

MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.

Day 4 EULAR Report

Save

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.

INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease

Save

B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.